95 related articles for article (PubMed ID: 38612609)
1. E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer.
Cheng C; Varn FS; Marsit CJ
Mol Cancer Res; 2015 Sep; 13(9):1316-24. PubMed ID: 26032289
[TBL] [Abstract][Full Text] [Related]
2. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Chamie K; Chang SS; Kramolowsky E; Gonzalgo ML; Agarwal PK; Bassett JC; Bjurlin M; Cher ML; Clark W; Cowan BE; David R; Goldfischer E; Guru K; Jalkut MW; Kaffenberger SD; Kaminetsky J; Katz AE; Koo AS; Sexton WJ; Tikhonenkov SN; Trabulsi EJ; Trainer AF; Spilman P; Huang M; Bhar P; Taha SA; Sender L; Reddy S; Soon-Shiong P
NEJM Evid; 2023 Jan; 2(1):EVIDoa2200167. PubMed ID: 38320011
[TBL] [Abstract][Full Text] [Related]
3. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Flaig TW; Spiess PE; Abern M; Agarwal N; Bangs R; Buyyounouski MK; Chan K; Chang SS; Chang P; Friedlander T; Greenberg RE; Guru KA; Herr HW; Hoffman-Censits J; Kaimakliotis H; Kishan AU; Kundu S; Lele SM; Mamtani R; Mian OY; Michalski J; Montgomery JS; Parikh M; Patterson A; Peyton C; Plimack ER; Preston MA; Richards K; Sexton WJ; Siefker-Radtke AO; Stewart T; Sundi D; Tollefson M; Tward J; Wright JL; Cassara CJ; Gurski LA
J Natl Compr Canc Netw; 2024 May; 22(4):216-225. PubMed ID: 38754471
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer.
Picard LC; Rich FJ; Kenwright DN; Stevens AJ
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(5):189123. PubMed ID: 38806074
[TBL] [Abstract][Full Text] [Related]
5. Atypical B cells promote cancer progression and poor response to Bacillus Calmette-Guérin in non-muscle invasive bladder cancer.
Yolmo P; Rahimi S; Chenard S; Conseil G; Jenkins D; Sachdeva K; Emon I; Hamilton J; Xu M; Rangachari M; Michaud E; Mansure JJ; Kassouf W; Berman DM; Siemens DR; Koti M
Cancer Immunol Res; 2024 Jun; ():. PubMed ID: 38916567
[TBL] [Abstract][Full Text] [Related]
6. Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review.
McNall S; Hooper K; Sullivan T; Rieger-Christ K; Clements M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791924
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
Narayan VM; Siolas D; Meadows ES; Turzhitsky V; Sillah A; Imai K; McMurry AJ; Li H
JCO Clin Cancer Inform; 2023 Sep; 7():e2300096. PubMed ID: 37906722
[TBL] [Abstract][Full Text] [Related]
8. Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer.
Zucca LER; Laus AC; Sorroche BP; Paro E; Sussuchi L; Marques RF; Teixeira GR; Berardinelli GN; Arantes LMRB; Reis RM; Cárcano FM
Transl Oncol; 2024 Aug; 46():102003. PubMed ID: 38838438
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
Khene ZE; Lotan Y
Expert Opin Biol Ther; 2024 Jun; ():1-9. PubMed ID: 38861054
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.
Tyagi P; Hafron J; Kaufman J; Chancellor M
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732167
[TBL] [Abstract][Full Text] [Related]
11. Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients.
Blichert-Refsgaard L; Graugaard-Jensen C; Nørgaard M; Jensen JB
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792014
[TBL] [Abstract][Full Text] [Related]
12. Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients.
Kong J; Zou Y; Zhou H; Huang Y; Lin Y; Fang S; Chen Z; Zheng J; Huang Y; Shen Z; Xie W; Fan X
Front Immunol; 2024; 15():1404812. PubMed ID: 38938564
[TBL] [Abstract][Full Text] [Related]
13. Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer.
Kang KA; Kim MJ; Kwon GY; Kim CK; Park SY
Abdom Radiol (NY); 2024 Jan; 49(1):163-172. PubMed ID: 37848639
[TBL] [Abstract][Full Text] [Related]
14. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Robertson AG; Meghani K; Cooley LF; McLaughlin KA; Fall LA; Yu Y; Castro MAA; Groeneveld CS; de Reyniès A; Nazarov VI; Tsvetkov VO; Choy B; Raggi D; Marandino L; Montorsi F; Powles T; Necchi A; Meeks JJ
Nat Commun; 2023 Apr; 14(1):2126. PubMed ID: 37105962
[TBL] [Abstract][Full Text] [Related]
15. A New Twist to an Old Tale: Immunotherapy in Non-muscle-invasive Bladder Cancer.
Funt SA; Pietzak EJ; Bajorin DF
Eur Urol Oncol; 2018 Aug; 1(3):199-201. PubMed ID: 31102621
[No Abstract] [Full Text] [Related]
16. Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.
Buonerba C; Ingenito C; Di Trolio R; Cappuccio F; Rubino R; Piscosquito A; Verde A; Costabile F; Iuliucci M; Crocetto F; Chiancone F; Nacchia A; Campitelli A; Scafuri L; Sanseverino R; Di Lorenzo G
Oncol Ther; 2024 Jun; 12(2):189-195. PubMed ID: 38416326
[TBL] [Abstract][Full Text] [Related]
17. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
Baek SW; Leem SH
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
[TBL] [Abstract][Full Text] [Related]
18. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
